Cell therapy in the cornea: The emerging role of microenvironment
- PMID: 38797320
- DOI: 10.1016/j.preteyeres.2024.101275
Cell therapy in the cornea: The emerging role of microenvironment
Abstract
The cornea is an ideal testing field for cell therapies. Its highly ordered structure, where specific cell populations are sequestered in different layers, together with its accessibility, has allowed the development of the first stem cell-based therapy approved by the European Medicine Agency. Today, different techniques have been proposed for autologous and allogeneic limbal and non-limbal cell transplantation. Cell replacement has also been attempted in cases of endothelial cell decompensation as it occurs in Fuchs dystrophy: injection of cultivated allogeneic endothelial cells is now in advanced phases of clinical development. Recently, stromal substitutes have been developed with excellent integration capability and transparency. Finally, cell-derived products, such as exosomes obtained from different sources, have been investigated for the treatment of severe corneal diseases with encouraging results. Optimization of the success rate of cell therapies obviously requires high-quality cultured cells/products, but the role of the surrounding microenvironment is equally important to allow engraftment of transplanted cells, to preserve their functions and, ultimately, lead to restoration of tissue integrity and transparency of the cornea.
Keywords: Cell therapy; Cornea; Endothelial cells; Extracellular matrix; Limbal stem cells; Microenvironment; Stroma; Transplantation.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest VGG is an employee of Holostem Terapie Avanzate, producing an Advanced Therapy Medicinal Product for corneal restoration. GF is an inventor on a patent pertaining to the use of Substance P antagonists for the treatment of LSCD.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
